Nycomed seeks to amend restrictions on $5.5bn of loans
Swiss private equity-owned pharmaceutical company Nycomed is expected to receive approval from its lenders to amend covenants on roughly $5.5bn after it improved the terms on offer. The original ones were rejected by some investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
